Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group

Annals of Neurology
P GajdosC Chastang

Abstract

We have conducted a trial to randomly assess the efficacy and tolerance of intravenous immunoglobulin (i.v.Ig) or plasma exchange (PE) in myasthenia gravis (MG) exacerbation and to compare two doses of i.v.Ig. Eighty-seven patients with MG exacerbation were randomized to receive either three PE (n = 41), or i.v.Ig (n = 46) 0.4 gm/kg daily further allocated to 3 (n = 23) or 5 days (n = 23). The main end point was the variation of a myasthenic muscular score (MSS) between randomization and day 15. The MSS variation was similar in both groups (median value, +18 in the PE group and +15.5 in the i.v.Ig group, p = 0.65). Similar efficacy, although slightly reduced in the 5-day group was observed with both i.v.Ig schedules. The tolerance of i.v.Ig was better than that of PE with a total of 14 side effects observed in 9 patients, 8 in the PE group and 1 in the i.v.Ig group (p = 0.01). Although our trial failed to show a pronounced difference in the efficacy of both treatments, it exhibited a very limited risk for i.v.Ig. i.v.Ig is an alternative for the treatment of myasthenic crisis. The small sample sizes in our trial, however, could explain why a difference in efficacy was not observed. Further studies are needed to compare PE with ...Continue Reading

References

Jan 9, 1992·The New England Journal of Medicine·J M Dwyer
Apr 1, 1991·Journal of Neurology·C AntozziF Fiacchino
Aug 1, 1991·Acta Neurologica Scandinavica·V CosiA Erbetta
Mar 1, 1991·Journal of Neurology, Neurosurgery, and Psychiatry·J D WatsonH Kronenberg
Nov 1, 1989·Clinical Immunology and Immunopathology·E Arsura
Jan 1, 1987·Annals of the New York Academy of Sciences·M E Seybold
Jul 1, 1986·Archives of Internal Medicine·E L ArsuraD Grob
Apr 14, 1984·Lancet·A Fateh-MoghadamR G Geursen
Feb 1, 1993·Archives of Neurology·E TanJ R Mendell

❮ Previous
Next ❯

Citations

Apr 15, 2000·Journal of Clinical Apheresis·R Weinstein
Jan 2, 2003·Annals of Neurology·Daniel B DrachmanRobert A Brodsky
Oct 16, 2002·Journal of Clinical Apheresis·Bruce C McLeod
Oct 4, 2002·Muscle & Nerve·Gil I WolfeUNKNOWN Myasthenia Gravis-IVIG Study Group
Feb 3, 2007·Der Nervenarzt·H C LehmannB C Kieseier
Mar 29, 2005·Zeitschrift für Rheumatologie·H MichelsF Buttgereit
Sep 26, 2006·Journal of Neurology·Isabel Ringel, Uwe K Zettl
Mar 5, 2009·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Lisa SartiSabrina Matà
Oct 12, 2010·Current Neurology and Neuroscience Reports·Vikas Kumar, Henry J Kaminski
Feb 5, 2004·Current Treatment Options in Neurology·Michael Graves, Jonathan S. Katz
Dec 11, 2003·Current Treatment Options in Neurology·Jawad F. KirmaniAdnan I. Qureshi
Dec 22, 2004·Current Treatment Options in Neurology·Vern C Juel, Janice M Massey
Dec 22, 2004·Current Treatment Options in Neurology·Neil C Porter, Brian C Salter
Jan 29, 2005·Current Treatment Options in Neurology·Shafiuddin AhmedAdnan I Qureshi
Sep 14, 2011·Current Treatment Options in Neurology·Hugh J McMillanPeter B Kang
Sep 24, 2009·Neurocritical Care·Logan M McDaneldAnish Bhardwaj
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ralf Gold, Christiane Schneider-Gold
Mar 25, 1998·Journal of the Neurological Sciences·M StangelR Gold
Nov 26, 2002·Clinical Neurology and Neurosurgery·Brian Wegner, Iftekhar Ahmed
Feb 11, 2000·Pediatric Neurology·D SelcenM A Nigro
May 7, 1998·Transfusion Science·J B Kuks, D Skallebaek
Mar 7, 1998·Neurophysiologie clinique = Clinical neurophysiology·M C DurandP Gajdos
Feb 6, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Janet B Kim, Mark Ballow
Oct 3, 2002·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·Ch GiraudL Guillevin
Jan 17, 2002·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·J M KorachUNKNOWN French Registry Study Group
Aug 28, 2003·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·J-M KorachUNKNOWN French Registry Study Group
Jan 6, 2007·Nature Clinical Practice. Neurology·Ralf GoldMarinos C Dalakas
Apr 16, 2002·Clinical and Experimental Dermatology·S Jolles
Jul 31, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·J H Yeh, H C Chiu
Jul 26, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·W F HauptC Birkmann
Jul 26, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·J M KorachP Chillet
Sep 7, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·A P BatocchiP Tonali
Sep 7, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·A I Qureshi, M F Suri
Jul 27, 2001·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·U E Nydegger, T Sturzenegger
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Robert M Pascuzzi
Sep 8, 2001·The New England Journal of Medicine·M D Kazatchkine, S V Kaveri
Mar 28, 2001·Ryōikibetsu shōkōgun shirīzu·A Suzumura
Jun 8, 2001·Clinical Neuropharmacology·O HilkevichA D Korczyn
Feb 21, 2002·La Revue du praticien·Philippe Gajdos
Aug 2, 2006·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Carol Lee Koski, Jardiolyn Valino Patterson
Dec 1, 2004·Journal of Clinical Neuromuscular Disease·Gil I Wolfe, Bella Gross
Mar 1, 2012·Journal of Clinical Neuromuscular Disease·Chad HeatwoleKatia Noyes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.